Developments in bioartificial liver research: Concepts, performance, and applications

Journal of Gastroenterology

Volumn 35, Issue 7, 2000, Pages 493-503

  Nagamori, Seishi ^a,c,d   Hasumura, Satoshi ^b   Matsuura, Tomokazu ^b   Aizaki, Hideki ^c   Kawada, Masaaki ^b  

^a KYORIN UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Albumin; Bioartificial liver; Bridging; Cytochrome P450; Extracorporeal circulatory system; Hepatocyte cell line; Radial flow bioreactor; Urea cycle

Indexed keywords

ANIMAL CELL; ARTIFICIAL LIVER; BIOREACTOR; CELL FUNCTION; CELL LINE; CELL PROLIFERATION; CELL TRANSPLANTATION; CELL VIABILITY; CONTROL SYSTEM; DRUG METABOLISM; ENZYME ACTIVITY; EXTRACORPOREAL CIRCULATION; HISTOCOMPATIBILITY; HUMAN; HUMAN CELL; LIVER CELL; LIVER FUNCTION; LIVER TRANSPLANTATION; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW;

EID: 0033924751     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005350070071     Document Type: Review

References (77)

1. Catapano G. Mass transfer limitations to the performance of membrane bioartificial liver support devices. Int J Artif Organs 1996;19:18-35.
2. Rozga J, Holzman MD, Ro M-S, Griffin DW, Neuzil DF, Giorgio T, et al. Development of a hybrid bioartificial liver. Artif Organs 1993;217:502-11.
3. Cattral MS, Levy GA. Artificial liver support - pipe dream or reality? New Engl J Med 1994;331:268-9.
4. Kasai S, Sawa M, Mito M. Is the biological artificial liver clinically applicable? A historic review of biological artificial liver support systems. Artif Organs 1994;18:348-54.
5. Kay MA, Faust N. Liver regeneration: prospects for therapy based on new technologies (review). Mol Med Today 1997;3:108-15.
6. Selden C, Shariat A, Mcloskey P, Ryder T, Roberts E, Hodgson H. Three-dimensional in vitro cell culture leads to a marked upregulation of cell function in human hepatocyte cell lines - an important tool for the development of a bioartificial liver machine. Ann NY Acad Sci 1999:353-63.
7. Dixit V, Gitnick G. Transplantation of microencapsulated hepatocytes for liver function replacement. J Biomater Sci Polymer Edn 1995;7:343-57.
8. Nagaki M, Kano T, Muto Y, Yamada T, Ohnishi H, Morikawa H. Effects of intraperitoneal transplantation of microcarrier-attached hepatocytes on D-galactosamine-induced acute liver failure in rats. J Gastroenterol 1990;25:78-87.
9. Dixit V. Transplantation of isolated hepatocytes and their role in extrahepatic life support systems. Scand J Gastroenterol 1995;30(Suppl 208):101-10.
10. Stange J, Mitzner S, Dauzenberg H, Ramlow W, Knippel M, Steiner M, et al. Prolonged biochemical and morphological stability of encapsulated liver cells. A new method. Biomater Artif Cells Immobilization Biotechnol 1993;21:343-52.
11. Demetriou AA, Levenson SM, Novikoff PM, Novikoff AB, Chowdhury NR, Whiting J, et al. Survival, organization, and microcarrier-attached hepatocytes transplanted in rats. Proc Natl Acad Sci USA 1986;83:7475-9.
12. Fremond B, Malandain C, Guyomard C, Chesne C, Guilouzo A, Campion J-P. Correction of bilirubin conjugation in the gunn rat using hepatocytes immobilized in alginate gel beads as an extra-corporeal bioartificial liver. Cell Transplant 1993;2:453-60.
13. Werner A, Duvar S, Muentemeyer J, Kahmann U, Luensdorf H, Lehmann J. Cultivation and characterization of a new immortalized human hepatocyte cell line, HepZ, for use in an artificial liver support system. Ann NY Acad Sci 1999;875:364-8.
14. Baquerizo A, Mhoyan A, Kearns-Jonker K, Arnaout AS, Shackleton C, Busuttil RW, et al. Characterization of human xenoreactive antibodies in liver failure patients exposed to pig hepatocytes after bioartificial liver treatment. Transplantation 1999;67:5-18.
15. Nyberg SL, Shatford RA, Peshwa MV, White JG, Cerra FB, Hu WS. Evaluation of a hepatocyte-entrapment hollow fiber bioreactor: a potential bioartificial liver. Biotech Bioeng 1993; 41:194-203.
16. Sielaff TD, Yu MY, Amiot B, Rollins MD, Rao S, MacGuire B, et al. Gel-entrapment bioreactor liver therapy in galactosamine hepatitis. J Surg Res 1995;59:179-84.
17. Shatford RA, Nyberg SL, Meier SJ, White JG, Payne WD, HulF W-S, et al. Hepatocyte function in a hollow fiber bioreactor: a potential bioartificial liver. J Surg Res 1992;53:549-57.
18. Sussman NL, Chong MG, Koussayer T, He D-E, Shang TA, Whisenhand HH, et al. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology 1992;16:60-5.
19. Takeshita K, Ishibashi H, Suzuki M, Yamamoto T, Akaike T, Kodama M. High cell density culture system of hepatocytes entrapped in a three-dimensional hollow fiber module with collagen gel. Artif Organs 1995;19:191-3.
20. LePage EB, Rozga J, Rosenthal JP, Watanabe F, Scott HC, Talke AM, et al. A bioartificial liver used as a bridge to liver transplantation in a 10-year-old boy. Am J Crit Care 1994;3:224-7.
21. Dixit V. Development of a bioartificial liver using isolated hepatocytes. Artif Organs 1994;18:371-84.
22. Sato Y, Ochiya T, Yasuda Y, Matsubara K. A new three-dimentional culture system for hepatocytes using reticulated polyurethane. Hepatology 1994;19:1023-8.
23. Kawada M, Nagamori S, Aizaki H, Fukaya K, Niiya M, Matsuura T. Massive culture of human liver cancer cells in a newly developed radial flow bioreactor system: ultrafine structure of functionally enhanced cell lines. In Vitro Cell Dev Biol 1998;34:109-15.
24. Stange J, Mitzner S. Cell sources for bioartificial liver support (review). Int J Artif Organs 1996;19:14-7.
25. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cell lines with differentiated functions in chemically defined medium, Cancer Res 1982;42:3858-63.
26. McLaughlin BE, Tosone CM, Custer LM, Mullon C. Overview of extracorporeal liver support system - clinical results. Ann NY Acad Sci 1999;875:310-25.
27. Nyberg SL, Shirabe K, Peshwa MV, Shielaff TD, Crotty PL, Mann HJ, et al. Extracorporeal application of a gel-entrapment, bioartificial liver: demonstration of drug metabolism and other biochemical functions. Cell Transplant 1993;2:441-52.
28. Aden DP, Fogel A, Plotkin S, Damjnov I, Knowles BB. Controlled synthesis of HBsAg in differentiated human liver carcinoma-derived cell line. Nature 1979;282:615-6.
29. Kuroki T, Huh N. Why are human cells resistant to malignant cell transformation in vitro? Jpn J Cancer Res 1993;84:1091-100.
30. Koebe HG, Schidberg FW. Isolation of porcine hepatocytes from slaughterhouse organs. Int J Artif Organs 1996;19:53-60.
31. Koebe HG, Paehrnik SA, Sproede M, Thasler WE, Schidberg FW. Porcine hepatocytes from slaughterhouse organs. An unlimited resource for bioartificial liver devices. ASAIO J 1995;41:189-93.
32. Takahashi M, Ishikawa H, Takahashi C, Nakajima Y, Matsushita M, Matsue H, et al. Immunologic considerations in the use of cultured porcine hepatocytes as a hybrid artificial liver. Anti-porcine hepatocyte human serum. ASAIO J 1993;39:M242-6.
33. Bader A, Knop E, Boeker K, Fruehauf N, Schuettler W, Oldhafer K. A novel design for in vitro reconstruction of in vivo liver characteristics. Artif Organs 1995;19:368-74.
34. Busse B, Gerlach JC. Bioreactors for hybrid liver support: historical aspects and novel designs. Ann NY Acad Sci 1999;875: 326-39.
35. Okamoto M, Ishida Y, Koegh A, Strain A. Evaluation of the function of primary human hepatocytes co-cultured with the human hepatic stellate cell (HSC) line LI90. Int J Artif Organs 1998;21:353-9.
36. Strain AS. Ex vivo liver cell morphogenesis: one step nearer to the bioartificial liver? Hepatology 1999;29:288-9.
37. Watanabe FD, Arnalout WS, Ting P, Navvaro A, Khalili T, Kamohara Y, et al. Artificial liver. Transplant Proc 1999;31:371-3.
38. Stange J, Mitzner SR, Risler T, Erley CM, Lauchart W, Goehl H. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999;23:319-30.
39. Demetriou AA, Rozga J, Podesta L, Lepage E, Morsiani E, Moscioni AD, et al. Early clinical experience with a hybrid bioartificial liver. Scand J Gastroenterol 1995;30(Suppl 208):111-7.
40. Jauregui HO, Mullon CJP, Trennker D, Naika S, Santangini H, Press P, et al. In vivo evaluation of a hollow fiber liver assist device. Hepatology 1995;21:460-9.
41. Li AP, Barker G, Beck D, Colburn S, Monsell R, Pellgrin C. Culturing of primary hepatocytes as entrapped aggregates in a packed bed bioreactor. A potential bioartificial liver. In Vitro Cell Dev Biol 1993;29A:249-54.
42. Hubbel JA, Langer R. Special report: tissue engineering. Washington: American Chemical Society; 1995. p. 42-54.
43. Baquerizo A, Mhoyan A, Shirwan H, Swensson J, Busuttil RW, Demetriou AA, et al. Xenoantibody response of patients with severe acute liver failure exposed to porcine antigens following treatment with a bioartificial liver. Tranplant Proc 1997;29: 964-5.
44. Sussman NL, Kelly JH. Improvement in liver function following treatment with an extracorporeal liver device. ASAIO Trans 1993;17:27-30.
45. Smith MD, Smithwaite AD, Cairns DE, Cousins RB, Gaylor JD. Techniques for measurement of oxygen consumption rates of hepatocytes during attachment and post-attachment. Int J Artif Organs 1996;19:36-44.
46. Foy BD, Lee J, Morgan J, Toner M, Tompkins RG, Yarmush ML. Opitimization of hepatocyte attachment to microcarriers: importance of oxygen. Biotech Bioeng 1992;42:579-88.
47. Nishikawa M, Uchino J, Matsushita M, Takahashi M, Taguchi M, Koike M, et al. Optimal oxygen tension conditions for functioning cultured hepatocytes in vitro. Artif Organs 1996;20:169-77.
48. Matsuura T, Kawada M, Hasumura S, Nagamori S, Obata T, Yamaguchi M. High density culture of immortalized liver endothelial cells in the radial-flow bioreactor in the development of an artificial liver. Int J Artif Organs 1998;21:229-34.
49. Yoshida H, Mizutani S, Ikenaga H. Scale-up of interleukin-6 production by BHK cells using a radial-flow reactor packed with porous glass beads. J Ferment Bioeng 1997;84:279-81.
50. Yoshida H, Mizutani S, Ikenaga H. Continuous production of erylhropoietin using a radial flow bioreactor. In: Sasaki R, Ikura K, editors. Animal cell culture and production of biologicals. Dordrecht: Kluwer Academic: 1990. p. 329-34.
51. Yoshida H, Mizutani S, Ikenaga H. Production of monoclonal antibodies with a radial flow bioreactor. In: Kaminogawa S, Ametani A, Hachimura S, editors. Animal cell technology: basic and applied aspects. Dordrecht: Kluwer Academic; 1992. p. 347-53.
52. Gerlach JC, Kloeppel K, Mueller C, Schnoy N, Smith MD, Neuhaus P. Hepatocyte aggregate culture technique for bioreactors in hybrid liver support systems. Int J Artif Organs 1993;16:843-6.
53. Hasumura S, Matsuura T, Aizaki H, Kawada M, Mizutani S, Nagamori S. A fine performance of albumin production of human liver cancer cell lines using a radial flow bioreactor (in Japanese with English abstract). Artificial Blood 1997;5:33-7.
54. Ledezma GA, Folch A, Bhatia SN, Balis UJ, Yarmush ML, Toner M. Numerical model of fluid flow and oxygen transport in a radial-flow microchannel containing hepatocytes. J Biomech Eng 1999; 121:58-64.
55. Nagamori S, Fujise K, Homma S, Sujino H, Matsuura T, Shimizu K, et al. Protein secretion of human cultured liver cells (in Japanese with English abstract). Human Cell 1988;1:382-90.
56. LePage EB, Lane R, McKay D, Rozga J, Demetriou AA. Plasma separation for liver support. J Clin Apheresis 1995;10:70-5.
57. Watanabe FD, Shackleton CR, Cohen SM, Goldman DE, Arnaout WS, Hewitt W, et al. Treatment of acetaminophen-induced fulminant hepatic failure with a bioreactor. Transplant Proc 1997;29:487-8.
58. Watanabe FD, Mullon CJ, Hewitt WR, Arkadopoulos N, Kahaku E, Eguchi S, et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg 1997;225:484-94.
59. Neuzil DF, Rozga J, Moscioni AD, Ro M-S, Hakim R, Arnaout WS, et al. Use of novel bioartificial liver in patient with acute liver insufficiency. Surgery 1993;113:340-3.
60. Holstege A, Lock G, Koellinger M, Schoelmrich J. Conservative treatment of acute hepatic failure. Z Gastroenterol 1996;34:192-201.
61. Lozga J, Podesta L, LePage E, Hoffman S, Morsiani E, Sher L, et al. Control of cerebral oedema by total hepatectomy and extracorporeal liver support in fulminant hepatic failure. Lancet 1993;342:898-9.
62. Koebe HG, Schildberg FW. The artificial liver - an interim report. Wien Klin Wochenschr 1998;110:551-63.
63. Thasler WE, Koebe HG, Pahernik SA, Schirdberg FW. Artificial liver on its way to clinical reality? (in German with English abstract). Zentralbl Chir 1995;120:614-23.
64. Velde AAt, Ladiges NCJJ, Flendrig LM, Chamlueau RAFM. Functional activity of isolated pig hepatocytes attached to different extracellular matrix substrates. Implication for application of pig hepatocytes in a bioartificial liver. J Hepatol 1995;23:184-92.
65. Kasai S, Mito M. Large-scale cryopreservation of isolated dog hepatocytes. Cryobiology 1993;30:1-11.
66. Gerlach J, Joerres A, Trost O, Hole O, Vienken J, Courtney JM, et al. Side effects of hybrid liver support therapy: TNF-α liberation in pigs, associated with extracorporeal bioreactors. Int J Artif Organs 1993;16:604-8.
67. Hu MY, Cipolle M, Sielaff T, Lovdahl MJ, Mann HJ, Remmel RP, et al. Effects of hepatocyte growth factor on viability and biotransformation functions of hepatocytes in gel entrapped and monolayer culture. Crit Care Med 1995;23:1237-42.
68. Nyberg SL, Mann HJ, Remmel RP, Hu W-S, Cerra FB. Pharmacokinetic analysis vertfies P450 function during in vitro and in vivo application of a bioartificial liver. ASAIO J 1993;39: M252-6.
69. Shimizu H. Experimental models of liver specific metabolism of environmental pollutants using human derived liver cells in a radial flow bioreactor. Japanese Ministry of Education, Basic science research (A2) report no. 08557033 (in Japanese and English). Tokyo: Japanese Ministry of Education, 1998.
70. Hughes RD, Nicolaou N, Langley PG, Ellis AJ, Wendon JA, Williams R. Plasma cytokine levels and coagulation and complement activation during use of the extracorporeal liver assist device in acute liver failure. Artif Organs 1998;22:854-8.
71. Cohen J. The scientific challenge of hepatitis C. Science 1999;285: 26-30.
72. Shimizu YK, Igarashi H, Kiyohara T, Shapiro M, Wong DC, Purcell RH, et al. Infection of chimpanzee with hepatitis C virus grown in cell culture. J Gen Virol 1998;79:1383-6.
73. Bassett SE, Thomas DL, Brasky KM, Lanford RE. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. J Virol 1999;73:1118-26.
74. Ito T, Mukaigawa J, Zuo J, Hirabayashi Y, Mitamura K, Yasui K. Cultivation of hepatitis C virus in primary hepatocytes culture from patients with chronic hepatitis C hepatitis results in release of high titre infectious virus. J Gen Virol 1996;77:1943-54.
75. Aizaki H, Nagamori S, Aoki Y, Ishii K, Suzuki T, Matsuura Y, et al. The utilization of human hepatocyte in the study of hepatitis C virus; establishment of the efficient replication system of hepatitis C virus (in Japanese with English abstract). Tiss Cult Res Commun 1999;18:265-78.
76. Aoki Y, Aizaki H, Shimoike T, Tani H, Ishii K, Saito I. A human liver cell line exhibits efficient translation of HCV RNAs produced by a recombinant adenovirus expressing T7 RNA polymerase. Virology 1998;250:140-50.
77. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-3.